Lu Xu
Impact in
- Drug Discovery top 10%
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- MicroRNA in disease regulation 4
- Breast Cancer Treatment Studies 3
- Cancer-related molecular mechanisms research 3
- Oncology 10
- Cancer Immunotherapy and Biomarkers 4
- HER2/EGFR in Cancer Research 4
- Co-authors
- Rong Qi (5 shared papers)Cong Chen (2 shared papers)Wuyuan Zhou (9 shared papers)Guomin Hu (1 shared paper)Youyi Zhang (1 shared paper)Hui Dai (1 shared paper)Han Xiao (1 shared paper)Cong Wen (1 shared paper)
- Journals
- BMC Cancer (2 papers)Journal of Functional Foods (2 papers)Journal of Immunotherapy (2 papers)Nanomedicine Nanotechnology Biology and Medicine (2 papers)Journal of Critical Care (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Lu Xu
46 papers receiving 1.2k citations
Lu Xu's Hit Papers
Peers
Comparison fields: 5 of 77
- Drug Discovery 6
- Oncology 241
- Cancer Research 115
- Epidemiology 251
- Geriatrics and Gerontology 19
Countries citing papers authored by Lu Xu
This map shows the geographic impact of Lu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Xu more than expected).
Fields of papers citing papers by Lu Xu
This network shows the impact of papers produced by Lu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Xu. The network helps show where Lu Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice Hit paper breakdown → | 2019 | 255 |
| 2 | 2016 | 110 | |
| 3 | 2020 | 88 | |
| 4 | 2017 | 79 | |
| 5 | 2021 | 64 | |
| 6 | 2018 | 62 | |
| 7 | 2017 | 37 | |
| 8 | 2015 | 33 | |
| 9 | Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. | 2018 | 30 |
| 10 | 2019 | 26 | |
| 11 | 2020 | 26 | |
| 12 | 2018 | 24 | |
| 13 | 2022 | 23 | |
| 14 | 2016 | 22 | |
| 15 | 2018 | 22 | |
| 16 | 2022 | 22 | |
| 17 | 2018 | 19 | |
| 18 | 2022 | 19 | |
| 19 | 2016 | 17 | |
| 20 | 2019 | 17 |
About Lu Xu
Lu Xu is a scholar working on Cancer Research, Oncology, Epidemiology, Pharmaceutical Science and Pharmacology, having authored 51 papers that have together received 1.2k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (7 papers), Cancer Immunotherapy and Biomarkers (4 papers), MicroRNA in disease regulation (4 papers), HER2/EGFR in Cancer Research (4 papers), Drug Solubulity and Delivery Systems (3 papers), Pancreatitis Pathology and Treatment (3 papers), Breast Cancer Treatment Studies (3 papers) and Cancer-related molecular mechanisms research (3 papers). The work is most often cited by research in Drug Discovery (6 citations), Oncology (241 citations), Cancer Research (115 citations), Epidemiology (251 citations) and Geriatrics and Gerontology (19 citations). Lu Xu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Rong Qi, Cong Chen, Wuyuan Zhou, Guomin Hu, Youyi Zhang, Hui Dai, Han Xiao, Cong Wen, Xuesong Liu and Haihong Wang. Their work appears in journals such as BMC Cancer, Journal of Functional Foods, Journal of Immunotherapy, Nanomedicine Nanotechnology Biology and Medicine and Journal of Critical Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.